Germany first EU country to launch COVID-19 therapy offensive?
After months of lobbying by the BIOM biotech cluster, Bavaria is launching a €50m initiative to push the best and fastest COVID-19 therapies.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2126 entries already.
Entries by Thomas Gabrielczyk
Moderna to file for EU approval of mRNA-1273 vaccine
COVID-19 mRNA vaccine developer Moderna Inc reported it will file for FDA and EMA authorisation of mRNA-1273 based on Phase III results.
Drug set to rescue COVID-19 patients at ICUs
Aviptadil, a vasodilator originally developed to treat erectile dysfunction, led to a 72% survival in critically-ill COVID-19 patients.
Rapid antibody development to cure COVID-19
In addition to vaccination programmes, the SARS-CoV-2 pandemic requires safe and efficient treatment options for patients infected and suffering from Covid-19 disease. Virus-neutralising antibody therapeutics can not only cure COVID-19 but also protect from infection. New fast-track antibody drug programmes have achieved unprecedented timelines from discovery to the clinics and give hope to save lives and cure COVID-19.
Polyphor AG bags funding for murepavadin
Polyphor has secured $3.3m from the Cystic Fibrosis Foundation as support for clinical Phase I/IIa testing of its inhaled antibiotic murepavadin.
25 years IZB
Commemorative publication for the 25th anniversary of the IZB presents 70 profiles and visions of successful biotech start-ups. The 360-page publication describes the development of the Innovation and Start- up Center for Biotechnology into the leading biotechnology center in Europe
Global bioeconomy in the spotlight
12 interactive workshops, five plenary sessions and more than 3,000 registered attendees – last week the Global Bioeconomy Summit brought together international experts to discuss major trends and developments.
A pioneering real AI drug discovery technology
The current COVID-19 pandemic situation has shown that repurposing drugs can be crucial for delivering new treatments to patients with agility. Existing drugs can be developed to bring fast, safe and cost-effective treatments for a wide range of conditions. The improved use of data and the development of advanced AI-based technologies enable the fast and effective identification of drugs, accelerating drug discovery, repurposing and innovation.
Collaborating to accelerate vaccine manufacturing
Development of the large-scale vaccine production process remains an inherently challenging undertaking. Given this complexity, it is more important than ever for vaccine manufacturers to collaborate with experienced technology providers. Such partners can provide critical support from development through manufacturing, helping to eliminate bottlenecks and accelerating production of urgently needed vaccines.
3,000+ experts discuss bioeconomy globally
More than 3,000 attendees are participating in the Global Bioeconomy Summit, currently taking place virtually until 20th November. Today, the plenary program and the livestream of the conference kicked-off.